KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Finished Goods (2023 - 2025)

Aurinia Pharmaceuticals' Finished Goods history spans 3 years, with the latest figure at $379000.0 for Q4 2025.

  • For Q4 2025, Finished Goods fell 58.03% year-over-year to $379000.0; the TTM value through Dec 2025 reached $379000.0, down 58.03%, while the annual FY2025 figure was $379000.0, 58.03% down from the prior year.
  • Finished Goods reached $379000.0 in Q4 2025 per AUPH's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.7 million in Q1 2025 to a low of $379000.0 in Q4 2025.
  • Average Finished Goods over 3 years is $1.6 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Finished Goods: soared 54.89% in 2024, then crashed 58.03% in 2025.
  • A 3-year view of Finished Goods shows it stood at $583000.0 in 2023, then skyrocketed by 54.89% to $903000.0 in 2024, then plummeted by 58.03% to $379000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Finished Goods are $379000.0 (Q4 2025), $1.4 million (Q3 2025), and $2.6 million (Q2 2025).